SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer
12 references·0 citing·38 second hop
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer (2013)A systematic review of cost-effectiveness…KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective (2011)KRAS and BRAF Mutation Analys…Cost‐effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany (2011)Cost‐effectiveness of KRAS te…Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial (2009)Prospective Cost-Effectivenes…How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question (2009)How Much Is Life Worth: Cetux…Cost implications of new treatments for advanced colorectal cancer (2009)Cost implications of new trea…The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales (2007)The cost-effectiveness of bev…Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment (2007)Cost-effectiveness analysis o…Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria (2005)Criteria list for assessment …The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal (2004)The quality of published heal…Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES (2003)Examining the Value and Quali…Should All Literature Reviews be Systematic? (2000)Should All Literature Reviews…Best evidence synthesis: An intelligent alternative to meta-analysis (1995)Combining Methods in Educational and Social Research (2004)Multi-criteria approaches for urban passenger transport systems: a literature review (2014)Simulation-optimization methods for designing and assessing resilient supply chain networks under uncertainty scenarios: A review (2020)Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998)National Institute for Clinical Excellence and its value judgments (2004)Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence? (2005)Clinical and economic challenges facing pharmacogenomics (2012)Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine (1994)Cost-Effectiveness in Health and Medicine (1996)Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis (1999)A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example (2009)Cost-Effectiveness Analyses in Orthopaedic Sports Medicine (2014)Patient-level costs in margin re-excision for breast-conserving surgery (2018)Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease (2002)The Health Utilities Index (HUI): concepts, measurement properties and applications. (2003)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Assessing the quality of reports of randomized clinical trials: Is blinding necessary? (1996)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? (1998)Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications (2008)Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2013)Cost-effectiveness evidence of mental health prevention and promotion interventions: A systematic review of economic evaluations (2021)Willingness to Pay for a Quality-adjusted Life Year (2000)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Preferences for cancer treatments: an overview of methods and applications in oncology (2012)Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer (2015)Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time (2018)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)The Value of Specialty Oncology Drugs (2009)Protocol of the COSMIN study: COnsensus-based Standards for the selection of health Measurement INstruments (2006)Economic evaluation of da Vinci-assisted robotic surgery: a systematic review (2011)AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users (2015)When is Cancer Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology (2010)Essential Epidemiology: An Introduction for Students and Health Professionals (2012)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 2005Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria858 cited
  • 2003Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES365 cited
  • 2009How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question351 cited
  • 2000Should All Literature Reviews be Systematic?163 cited
  • 2009Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial139 cited
  • 2004The quality of published health economic analyses in digestive diseases: A systematic review and quantitative appraisal95 cited
  • 2007The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales84 cited
  • 2007Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment79 cited
  • 2011KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective66 cited
  • 2011Cost‐effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany65 cited
  • 2009Cost implications of new treatments for advanced colorectal cancer61 cited

Cited by

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

No citing works inside the corpus for this window.